A simple urine test measuring methylation at a DNA marker called TAGMe may help doctors assess how aggressive a urothelial carcinoma is before surgery, according to a study published in BMC Medicine. The research, led by Qing Chen, Ziwei Wang and colleagues, builds on TAGMe’s earlier development as a non-invasive marker for detecting urothelial carcinoma and now extends its use to predicting recurrence, progression and survival.
Urothelial carcinoma, which includes bladder cancer, is marked by substantial molecular heterogeneity, making accurate risk stratification difficult with current tools. Because treatment decisions often hinge on judging tumor aggressiveness before an operation, the researchers set out to test whether a marker measurable in urine could add prognostic information beyond what conventional clinicopathological variables provide.
The team measured preoperative urinary TAGMe methylation using a methylation-sensitive restriction enzyme quantitative PCR assay in 375 patients with urothelial carcinoma. They then analyzed the methylation levels in relation to clinicopathological features and survival outcomes, applying Kaplan–Meier curves and Cox regression models to assess associations with patient prognosis.
The results showed that preoperative TAGMe levels were associated with adverse pathological features and with poorer recurrence-free, progression-free and overall survival. In other words, patients whose urine showed higher methylation at this marker tended to fare worse across multiple measures of disease outcome, suggesting the marker captures biologically meaningful differences in tumor behavior.
To translate this into clinical utility, the researchers integrated TAGMe with conventional clinicopathological variables to build prognostic models and a nomogram, a scoring tool that combines several factors into an individualized risk estimate. Evaluation using the concordance index and time-dependent ROC analysis showed that adding TAGMe improved risk discrimination beyond conventional variables alone. Notably, the marker also refined risk stratification within established pathological subgroups, indicating it may offer information that current staging and grading systems miss.
Beyond its prognostic performance, the study probed what TAGMe actually does biologically. Using multi-omics analyses that integrated ATAC-seq, Hi-C, ChIP-seq, CUT&RUN and TCGA data, the researchers found that the TAGMe locus sits within an active enhancer-like region marked by the histone modifications H3K27ac and H3K4me1, and that this region physically interacts with the locus of a long non-coding RNA called BHLHE40-AS1.
Follow-up experiments clarified the relationship. TAGMe activated BHLHE40-AS1 transcription in a methylation-dependent manner, and TAGMe hypermethylation correlated with reduced BHLHE40-AS1 expression. Functional assays in bladder cancer cells then demonstrated that BHLHE40-AS1 suppresses proliferation, migration and epithelial–mesenchymal transition, processes central to tumor growth and spread. Dual-luciferase assays, DNA demethylation experiments and gain-of-function studies were used to validate the enhancer activity of TAGMe and the functional role of the lncRNA.
These findings sketch a mechanistic link between intergenic DNA methylation and tumor progression: methylation changes at a non-coding region in the genome can alter the expression of a regulatory RNA, which in turn influences cancer cell behavior. The authors conclude that urinary TAGMe methylation may complement conventional clinicopathological factors for preoperative risk stratification in urothelial carcinoma, while the methylation-sensitive TAGMe–BHLHE40-AS1 enhancer axis provides a biological explanation for why the marker tracks with aggressive disease.
As with any biomarker study, the associations reported here will require further validation before routine clinical adoption, and the functional work was performed in cell models rather than patients. Nevertheless, the study suggests that a urine-based epigenetic marker could one day help clinicians weigh surgical decisions with a clearer picture of each patient’s likely outcome, obtained non-invasively before the operation begins.
Subject of Research: Urinary TAGMe DNA methylation as a non-invasive prognostic biomarker and enhancer regulator in urothelial carcinoma
Article Title: Urinary TAGMe methylation enables preoperative risk stratification and reveals enhancer‑mediated regulation in urothelial carcinoma
Article References: Chen, Q., Wang, Z., He, W., Zhang, C., Wang, M., Wang, Y., Yu, X., Zhu, Y., Dong, Y., Yang, Z., Dong, S., Xu, P., Li, W., Zeng, S., Yu, W., & Xu, C. (2026). Urinary TAGMe methylation enables preoperative risk stratification and reveals enhancer‑mediated regulation in urothelial carcinoma. BMC Medicine. https://doi.org/10.1186/s12916-026-05341-6
Image Credits: AI Generated
DOI: 10.1186/s12916-026-05341-6
Keywords: urothelial carcinoma, bladder cancer, DNA methylation, TAGMe, liquid biopsy, biomarker, risk stratification, BHLHE40-AS1, enhancer, lncRNA, epigenetics, nomogram
News Source: Nathaniel Bowman. (October 27, 2026). Urinary DNA methylation marker TAGMe offers preoperative risk stratification in urothelial carcinoma. Scienmag.
